

**Table 2:** Medications and clinical outcomes of the patients stasis regarding dermatitis diagnosis within six months preceding admission to heart failure outpatient clinic.

	<b>Group 1 SD (+)</b> <b>(n =41)</b>	<b>Group SD (-)</b> <b>(n =117)</b>	<b>p</b>
<b>HF-related medications (n=148)</b>			
<b>Usage of ACEI/ARB (%)</b>	26 (72%)	81 (72%)	1.000
<b>Usage of MRA (%)</b>	21 (58%)	55(49%)	0.440
<b>Usage of Beta Blocker (%)</b>	27 (75%)	97 (87%)	0.166
<b>Usage of Digoxin (%)</b>	10 (28%)	29 (26%)	0.995
<b>Usage of Diuretics (%)</b>	30 (83%)	97 (87%)	0.830
<b>Clinical outcomes</b>			
<b>HF-related hospitalization (%)</b>	29 (71%)	29 (25%)	<b>&lt;0.001</b>
<b>Cardiovascular death (%)</b>	7 (17%)	22 (19%)	0.991

SD: stasis dermatitis, HF: heart failure, ACEI: angiotensinogen converting enzyme inhibitor, ARB: angiotensin receptor blocker, MRA: mineralocorticoid receptor antagonist.